Outcomes of Warfarin and Rivaroxaban (Xalerban) consumption in patients with Atrial fibrillatio

Phase 4

Recruiting

• Conditions: Atrial fibrillation.; Chronic atrial fibrillation; I48.2

• Registration Number: IRCT20170530034232N2
• Lead Sponsor: Vice-Chancellor For Research and Technology of Guilan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 330

Inclusion Criteria

Being over 50 years old
Patients with Atrial fibrillation
CHAD2S2 Vasc Score more than 1

Exclusion Criteria

Patient's dissatisfaction with the study
Wolff Parkinson White Syndrome
Allergic to any of the drugs Rivaroxaban (Xalerban) and warfarin
Abnormal Creatinine level
Thrombocytopenia

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bleeding. Timepoint: All patients will be followed up by researchers every 15 days in the first month and then every month for 6 month. Method of measurement: Measurement of coagulation factors and hemoglobin level by blood test.

Secondary Outcome Measures

Name	Time	Method
Changes in liver's enzymes. Timepoint: All patients will be followed up by researchers every 15 days in the first month and then every month for 6 month. Method of measurement: Measurement of liver's enzymes (SGOT, SGPT) by blood test.